Your browser doesn't support javascript.
loading
Patterns of Hearing Loss in Irradiated Survivors of Head and Neck Rhabdomyosarcoma.
Diepstraten, Franciscus A; Wiersma, Jan; Schoot, Reineke A; Knops, Rutger R G; Zuur, Charlotte L; Meijer, Annelot J M; Dávila Fajardo, Raquel; Pieters, Bradley R; Balgobind, Brian V; Westerveld, Henrike; Freling, Nicole; van Tinteren, Harm; Smeele, Ludwig E; Bel, Arjan; van den Heuvel-Eibrink, Marry M; Stokroos, Robert J; Merks, Johannes H M; Hoetink, Alexander E; Hol, Marinka L F.
Affiliation
  • Diepstraten FA; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Wiersma J; Department of Radiation Oncology, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • Schoot RA; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Knops RRG; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Zuur CL; Department of Head and Neck Surgery, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
  • Meijer AJM; Department of Otorhinolaryngology Head and Neck Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
  • Dávila Fajardo R; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Pieters BR; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Balgobind BV; Department of Radiation Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.
  • Westerveld H; Department of Radiation Oncology, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • Freling N; Amsterdam Cancer Center, Cancer Treatment and Quality of Life, 1081 HV Amsterdam, The Netherlands.
  • van Tinteren H; Department of Radiation Oncology, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • Smeele LE; Amsterdam Cancer Center, Cancer Treatment and Quality of Life, 1081 HV Amsterdam, The Netherlands.
  • Bel A; Department of Radiation Oncology, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • van den Heuvel-Eibrink MM; Amsterdam Cancer Center, Cancer Treatment and Quality of Life, 1081 HV Amsterdam, The Netherlands.
  • Stokroos RJ; Department of Radiology, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • Merks JHM; Trial and Data Center, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Hoetink AE; Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  • Hol MLF; Department of Head and Neck Surgery, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Cancers (Basel) ; 14(23)2022 Nov 23.
Article in En | MEDLINE | ID: mdl-36497230
ABSTRACT

PURPOSE:

The frequency and patterns of HL in a HNRMS survivor cohort were investigated. A dose-effect relationship between the dose to the cochlea and HL was explored.

METHODS:

Dutch survivors treated for HNRMS between 1993 and 2017 with no relapse and at least two years after the end of treatment were eligible for inclusion. The survivors were evaluated for HL with pure-tone audiometry. HL was graded according to the Muenster, Common Terminology Criteria for Adverse Events (CTCAE) v4.03 and International Society for Paediatric Oncology (SIOP) classification. We defined deleterious HL as Muenster ≥ 2b, CTCAE ≥ 2, and SIOP ≥ 2. Mixed-effects logistic regression was used to search for the dose-effect relationship between the irradiation dose to the cochlea and the occurrence of HL.

RESULTS:

Forty-two HNRMS survivors underwent pure-tone audiometry. The Muenster, CTCAE and SIOP classification showed that 19.0% (n = 8), 14.2% (n = 6) and 11.9% (n = 5) of survivors suffered from HL, respectively. A low-frequency HL pattern with normal hearing or milder hearing loss in the higher frequencies was seen in four survivors. The maximum cochlear irradiation dose was significantly associated with HL (≥Muenster 2b) (p = 0.047). In our series, HL (≥Muenster 2b) was especially observed when the maximum dose to the cochlea exceeded 19 Gy.

CONCLUSION:

HL occurred in up to 19% of survivors of HNRMS. More research is needed on HL patterns in HNRMS survivors and on radiotherapy dose-effect relationships.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2022 Document type: Article Affiliation country: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2022 Document type: Article Affiliation country: Netherlands